Highlights Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Market Closed - Nasdaq Other stock markets 01:30:00 17/05/2024 am IST			5-day change	1st Jan Change
2.25 ^USD	-4.26%		+3.21%	-67.49%

10/05	Immix Biopharma, Inc. Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Latebreaking Oral Presentation	CI
09/05	Immix Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immix Biopharma, Inc. Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Latebreaking Oral Presentation	10/05	CI
Immix Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment	30/04	MT
Immix Biopharma on Track to Dose First Patients with AL Amyloidosis Therapy by Mid-Year	19/04	MT
Immix Biopharma, Inc. Announces on Track to Dose NXC-201 Patients in United States	18/04	CI
Immix Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03	CI
Immix Biopharma, Inc. Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 Al Amyloidosis Clinical Trial	20/03	CI
Immix Biopharma, Inc. Announces New Clinical Data from Its Phase 1b/2a NEXICART-1	11/12	CI
Immix Biopharma, Inc. to Host KOL Event to Discuss Its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis	22/11	CI
Immix Biopharma Says FDA Clears Investigational New Drug Application for NXC-201; Shares Fall	21/11	MT
Immix Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients	06/11	CI
Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site	16/23/16	CI
Immix Biopharma, Inc. Announces Complete Response in 9Th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial At IMS 20Th Annual Meeting	03/23/03	CI
Immix Biopharma Inc. Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma	02/23/02	CI
Immix Biopharma Gets FDA Orphan Drug Label For NXC-201 to Treat Amyloid Light Chain Amyloidosis	21/23/21	MT
Immix Biopharma, Inc Announces U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma	23/23/23	CI
Immix Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	12/23/12	CI
Immix Biopharma, Inc. Reports 2Nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1B/2A Imx-110 Imx-110 Clinical Trial	17/23/17	CI
Immix Biopharma Unit Nexcella Completes First NXC-201 Engineering Batch at US Site; Shares Rise	10/23/10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Highlights

Filters